Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CCR8 | P51685 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19272315 | 0.92 | KDM4E (0.47) | ENPP2KDM4EALDH1A1S1PR5SMN1; SMN2 | |
| SCHEMBL18532853 | 0.92 | ALDH1A1 (0.62) | KDM4EALDH1A1SMN1; SMN2L3MBTL1ATM | |
| SCHEMBL11025167 | 0.92 | ALDH1A1 (0.62) | KDM4EALDH1A1SMN1; SMN2L3MBTL1ATM | |
| SCHEMBL1162183 | 0.92 | ALDH1A1 (0.62) | KDM4EALDH1A1SMN1; SMN2L3MBTL1ATM | |
| SCHEMBL11942426 | 0.92 | ALDH1A1 (0.62) | KDM4EALDH1A1SMN1; SMN2L3MBTL1ATM | |
| SCHEMBL11942427 | 0.92 | ALDH1A1 (0.62) | KDM4EALDH1A1SMN1; SMN2L3MBTL1ATM | |
| SCHEMBL18532922 | 0.92 | ALDH1A1 (0.62) | KDM4EALDH1A1SMN1; SMN2L3MBTL1ATM | |
| SCHEMBL1162184 | 0.92 | ALDH1A1 (0.62) | KDM4EALDH1A1SMN1; SMN2L3MBTL1ATM | |
| SCHEMBL1161788 | 0.91 | KDM4E (0.57) | KDM4EALDH1A1S1PR5SMN1; SMN2MAPT | |
| SCHEMBL12472059 | 0.91 | KDM4E (0.57) | KDM4EALDH1A1S1PR5SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190209592-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209592-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR3, S1PR4 | ENPP2 32/4885KDM4E 3227/4885ALDH1A1 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.